Effect of extracorporeal membrane oxygenation combined with hemoperfusion on inflammatory factors in patients with cardiogenic shock

Table 3 Complications and prognosis in two groups, n (%)

	ECMO (n = 42)	ECMO+HP (n = 39)	P value
Hemorrhage	13 (31.0)	12 (30.8)	0.986
Infection	22 (56.4)	17 (43.6)	0.429
Central nervous system dysfunction	5 (11.9)	4 (10.3)	0.723
Use of intra-aortic balloon pumping	34 (81.0)	31 (79.5)	0.774
Use of continuous renal replacement therapy	17 (40.5)	21 (53.8)	0.228
ECMO operation time, hour	135.0 (73.0, 199.3)	114.0 (75.0, 139.0)	0.046
Successful weaning of ECMO	18 (42.9)	26 (66.7)	0.013
SOFA after weaning	9 (8, 10)	7 (6, 8)	< 0.001
SIRS after weaning	11 (26.2)	4 (10.3)	0.077
Vasoactive-inotropic score	9.8 1.6	8.4 1.3	< 0.001
Duration of hospitalization, d	23 (13, 45.3)	22 (10, 41)	0.762
In-hospital survival	22 (52.4)	25 (64.1)	0.285
30-day survival	15 (38.5)	18 (46.2)	0.492
90-day survival	13 (33.3)	16 (41.0)	0.482

ECMO: Extracorporeal membrane oxygenation; HP: Hemoperfusion; SOFA: Sequential Organ Failure Assessment score; SIRS: Systemic inflammatory response syndrome.